In order to strengthen its rare disease franchise, Recordati has agreed to acquire the global rights to Sanofi’s Enjaymo® (sutimlimab) for US$825 M upfront and up to US$250 M in milestone payments. Enjaymo is a humanised monoclonal antibody which is the first and only treatment indicated to decrease the need for red blood cell transfusion due to haemolysis in adults with cold agglutinin disease (CAD), a rare B-cell lymphoproliferative disorder. The agreement marks yet another move by Sanofi to streamline its portfolio and focus in on lucrative areas of research such as immunology and inflammation.